Fundación Hospital Alcorcón -ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2016

  1. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease

    Journal of Neurology, Vol. 263, Núm. 7, pp. 1390-1400

2014

  1. A restricted population of CB1 cannabinoid receptors with neuroprotective activity

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, Núm. 22, pp. 8257-8262

2011

  1. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease

    Brain, Vol. 134, Núm. 1, pp. 119-136

  2. Prospects for cannabinoid therapies in basal ganglia disorders

    British Journal of Pharmacology, Vol. 163, Núm. 7, pp. 1365-1378

2009

  1. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity

    Brain, Vol. 132, Núm. 11, pp. 3152-3164

2008

  1. The CB2 cannabinoid receptor controls myeloid progenitor trafficking: Involvement in the pathogenesis of an animal model of multiple sclerosis

    Journal of Biological Chemistry, Vol. 283, Núm. 19, pp. 13320-13324

2007

  1. Cannabinoid CB2 receptor: a new target for controlling neural cell survival?

    Trends in Pharmacological Sciences, Vol. 28, Núm. 1, pp. 39-45